It has been shown that RPS23RG1 and RPS23RG2 can interact with adenylyl cyclase and upregulate cAMP levels, which further increases PKA activity, thereby limiting the activity of GSK-3, reducing Aβ production and tau hyperphosphorylation to resist the development of AD (Zhang et al., 2009; Hipp et al., 2019). This evidence concerns the gene MAPT and Alzheimer disease.